CL2019001698A1 - Suministro de proteínas basado en bacterias con virulencia atenuada. - Google Patents

Suministro de proteínas basado en bacterias con virulencia atenuada.

Info

Publication number
CL2019001698A1
CL2019001698A1 CL2019001698A CL2019001698A CL2019001698A1 CL 2019001698 A1 CL2019001698 A1 CL 2019001698A1 CL 2019001698 A CL2019001698 A CL 2019001698A CL 2019001698 A CL2019001698 A CL 2019001698A CL 2019001698 A1 CL2019001698 A1 CL 2019001698A1
Authority
CL
Chile
Prior art keywords
bacteria
protein delivery
attenuated virulence
delivery based
virulence
Prior art date
Application number
CL2019001698A
Other languages
English (en)
Inventor
Simon Ittig
Marlise Amstutz
Christoph Kasper
Original Assignee
Univ Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Basel filed Critical Univ Basel
Publication of CL2019001698A1 publication Critical patent/CL2019001698A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A CEPAS BACTERIANAS GRAMNEGATIVAS CON VIRULENCIA ATENUADA RECOMBINANTES Y SU USO EN UN MÉTODO PARA TRATAR EL CÁNCER EN UN SUJETO.
CL2019001698A 2016-12-20 2019-06-19 Suministro de proteínas basado en bacterias con virulencia atenuada. CL2019001698A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16205439 2016-12-20

Publications (1)

Publication Number Publication Date
CL2019001698A1 true CL2019001698A1 (es) 2020-01-24

Family

ID=57629346

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001698A CL2019001698A1 (es) 2016-12-20 2019-06-19 Suministro de proteínas basado en bacterias con virulencia atenuada.

Country Status (29)

Country Link
US (2) US11518789B2 (es)
EP (2) EP3957645A1 (es)
JP (1) JP6976351B2 (es)
KR (1) KR102569949B1 (es)
CN (2) CN110325545B (es)
AU (1) AU2017384611B2 (es)
BR (1) BR112019012338A2 (es)
CA (1) CA3046852A1 (es)
CL (1) CL2019001698A1 (es)
CO (1) CO2019006675A2 (es)
CY (1) CY1124488T1 (es)
DK (1) DK3559022T3 (es)
EA (1) EA201991157A1 (es)
ES (1) ES2886672T3 (es)
HR (1) HRP20211516T1 (es)
HU (1) HUE055832T2 (es)
IL (1) IL267346A (es)
LT (1) LT3559022T (es)
MA (1) MA47119B1 (es)
MX (1) MX2019007264A (es)
MY (1) MY192537A (es)
NZ (1) NZ754510A (es)
PE (1) PE20191356A1 (es)
PH (1) PH12019550092A1 (es)
PL (1) PL3559022T3 (es)
PT (1) PT3559022T (es)
RS (1) RS62303B1 (es)
SI (1) SI3559022T1 (es)
WO (1) WO2018115140A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115960919A (zh) 2014-05-21 2023-04-14 巴塞尔大学 基于细菌的蛋白质递送
HUE051184T2 (hu) 2015-11-19 2021-03-01 Univ Basel Baktériumalapú fehérjeszállítás
AU2016358257B2 (en) 2015-11-19 2023-08-17 Universitat Basel Virulence attenuated bacteria for treatment of malignant solid tumors
WO2017123675A1 (en) 2016-01-11 2017-07-20 Synlogic, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
PT3559022T (pt) 2016-12-20 2021-08-19 Univ Basel Distribuição de proteínas baseada em bactérias com virulência atenuada
EP3847236A4 (en) * 2018-09-06 2022-06-08 Dana-Farber Cancer Institute, Inc. CGAS/DNCV-LIKE NUCLEOTIDYL TRANSFERASES AND USES THEREOF
CN109825464B (zh) * 2019-01-17 2021-06-15 浙江海洋大学 敲除t6ss-1基因簇的杀香鱼假单胞菌鱼用减毒疫苗
WO2021076897A1 (en) * 2019-10-18 2021-04-22 University Of Virginia Patent Foundation Compositions and methods for producing enhanced immune responses and rapid antibody production
US20230364162A1 (en) * 2020-09-28 2023-11-16 The Regents Of The University Of Michigan Methods and compositions for intestinal inflammation
KR20230098197A (ko) * 2020-10-27 2023-07-03 티3 파마슈티컬스 아게 세균 기반한 단백질 전달
WO2022164937A1 (en) * 2021-01-26 2022-08-04 Christopher Bradley Treatment of cancer using mrna-mediated virus vaccination antigens delivered by attenuated bacteria
CN112852698B (zh) * 2021-01-30 2022-11-29 军事科学院军事医学研究院军事兽医研究所 牛种布鲁氏菌A19株asd基因缺失株的构建方法和应用
WO2022200492A1 (en) * 2021-03-25 2022-09-29 T3 Pharmaceuticals Ag Pharmaceutical combinations for treating cancer
CN117440829A (zh) * 2021-03-25 2024-01-23 T3制药股份公司 用于治疗癌症的药物组合
CN113480611B (zh) * 2021-06-28 2022-12-02 武汉大学 Rig-i的半胱天冬酶激活募集结构域抗病毒多肽、载体及其在制备抗病毒药物中的应用
CN113699088B (zh) * 2021-08-27 2023-09-15 集美大学 一株溶藻弧菌pstS基因稳定沉默菌株及其应用
CN114181881A (zh) * 2021-12-15 2022-03-15 浙江农林大学 基于氨基酸改造的新型减毒单增李斯特菌构建方法及应用
WO2023164454A2 (en) * 2022-02-22 2023-08-31 Board Of Regents For The Oklahoma Agricultural And Mechanical Colleges Compositions and methods for improved rhizobium-mediated plant transformation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965381A (en) * 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia
WO2000002996A2 (en) 1998-07-10 2000-01-20 Cornell Research Foundation, Inc. Recombinant constructs and systems for secretion of proteins via type iii secretion systems
US6291245B1 (en) * 1998-07-15 2001-09-18 Roche Diagnostics Gmbh Host-vector system
WO2002026819A2 (en) * 2000-09-26 2002-04-04 Roger Williams Hospital Recombinant bcg vaccines for the prevention and treatment of cancer
WO2002077249A2 (en) 2001-03-26 2002-10-03 Universite Catholique De Louvain Type iii bacterial strains for use in medicine
FR2862312B1 (fr) 2003-11-13 2006-02-17 Univ Grenoble 1 Outil de transfert et de production de proteines mettant en oeuvre le systeme de secretion de type iii de pseudomonas
JP2009510169A (ja) * 2005-10-04 2009-03-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 細菌抗原送達系を用いた免疫応答を刺激するための方法
WO2008019183A2 (en) 2006-05-18 2008-02-14 The Regents Of The University Of California Biopolymer and protein production using type iii secretion systems of gram negative bacteria
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
AU2009226972B2 (en) 2008-03-17 2014-05-29 Gerhard Heusipp YopM as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions
AU2015227479B2 (en) * 2008-11-21 2017-05-04 Københavns Universitet (University Of Copenhagen) Priming of an immune response
US9951340B2 (en) * 2013-03-07 2018-04-24 The General Hospital Corporation Compositions and methods for bacterial delivery of polypeptides
CN113563478A (zh) 2013-09-24 2021-10-29 梅迪塞纳医疗股份有限公司 白介素-4受体结合融合蛋白及其应用
US10143743B2 (en) 2013-11-18 2018-12-04 Yale University Non-replicating bacterial nanoparticle delivery system and methods of use
CN115960919A (zh) 2014-05-21 2023-04-14 巴塞尔大学 基于细菌的蛋白质递送
HUE051184T2 (hu) 2015-11-19 2021-03-01 Univ Basel Baktériumalapú fehérjeszállítás
AU2016358257B2 (en) 2015-11-19 2023-08-17 Universitat Basel Virulence attenuated bacteria for treatment of malignant solid tumors
PT3559022T (pt) 2016-12-20 2021-08-19 Univ Basel Distribuição de proteínas baseada em bactérias com virulência atenuada

Also Published As

Publication number Publication date
EP3957645A1 (en) 2022-02-23
US20230250138A1 (en) 2023-08-10
MA47119A (fr) 2019-10-30
EP3559022B1 (en) 2021-06-30
BR112019012338A2 (pt) 2019-11-26
EA201991157A1 (ru) 2020-01-16
MX2019007264A (es) 2019-11-18
DK3559022T3 (da) 2021-09-27
KR20190097154A (ko) 2019-08-20
CN110325545A (zh) 2019-10-11
SI3559022T1 (sl) 2021-11-30
AU2017384611A1 (en) 2019-07-04
LT3559022T (lt) 2021-08-25
CA3046852A1 (en) 2018-06-28
CN110325545B (zh) 2024-02-09
ES2886672T3 (es) 2021-12-20
RS62303B1 (sr) 2021-09-30
PH12019550092A1 (en) 2020-03-09
AU2017384611B2 (en) 2022-10-27
CO2019006675A2 (es) 2019-09-18
KR102569949B1 (ko) 2023-08-24
US11518789B2 (en) 2022-12-06
JP6976351B2 (ja) 2021-12-08
CN118006531A (zh) 2024-05-10
HUE055832T2 (hu) 2021-12-28
HRP20211516T1 (hr) 2021-12-24
WO2018115140A2 (en) 2018-06-28
US20200123207A1 (en) 2020-04-23
PE20191356A1 (es) 2019-10-01
WO2018115140A3 (en) 2018-08-09
JP2020501609A (ja) 2020-01-23
PT3559022T (pt) 2021-08-19
MY192537A (en) 2022-08-26
CY1124488T1 (el) 2022-07-22
EP3559022A2 (en) 2019-10-30
PL3559022T3 (pl) 2021-12-20
MA47119B1 (fr) 2021-09-30
NZ754510A (en) 2024-02-23
IL267346A (en) 2019-08-29

Similar Documents

Publication Publication Date Title
CL2019001698A1 (es) Suministro de proteínas basado en bacterias con virulencia atenuada.
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
AU2017260389A1 (en) Chimeric neurotoxins
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
MX2021004479A (es) Agentes biologicos y su uso en plantas.
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
CL2017002050A1 (es) Uso de plinabulina en combinación con inhibidores de punto de control inmunitario
MD3209381T2 (ro) Compoziții care conțin tulpini bacteriene
MX2016009898A (es) Tratamientos para acne resistente.
BR112016023707A2 (pt) método para produzir l-aminoácidos com o uso de uma bactéria alcalifílica
BR112018009753A2 (pt) bactérias de virulência atenuada para o tratamento de tumores sólidos malignos
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112017009265A2 (pt) apilimode para uso no tratamento do câncer colorretal
IN2014MU01100A (es)
CL2019001002A1 (es) Métodos y composiciones para inmunoterapia por tusc2.
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
MX2019008779A (es) Antigenos de pseudomonas y combinaciones de antigenos.
IL256162A (en) An amino thiol for use in the treatment of an infection caused by the bacterium mycobacterium spp.
BR112019003112A2 (pt) bactérias
AR115575A1 (es) Antagonista gremlin-1 para la prevención y tratamiento del cáncer
UA96801U (uk) Спосіб обробки водно-спиртової суміші